WCN25-4404 SUCCESSFUL TRANSPLANTATION OF LIVE DONOR KIDNEY WITH A LARGE ANGIOMYOLIPOMA: A CASE REPORT

42.12 -74.24) and 52.88 ((41.76-64.43)ml/min, with P-values of 0.08 and 0.417.Biopsy proven rejection rates were comparable between the groups, with ATG at 26.4% and Basiliximab at 27% (P 0.948) Three-year graft survival was 85.7% in the ATG group and 90.9% in the Basiliximab group, with no statistically significant difference (P 0.733).Though infections were numerically more in anti thymocyte globulin group than basiliximab but were not statistically significant.Conclusions: In conclusion, both ATG and Basiliximab groups exhibited similar eGFR values at one and three years, with no significant differences in biopsy-proven rejection rates or three-year graft survival.This suggest comparable efficacy between ATG and Basiliximab in terms of graft function and survival.year graft survival.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.